The International Lecture Series ‘Disease Biology and Molecular Medicine’ brings to Halle’s historic city center renowned researchers from world-leading institutions to share their latest research findings. Set in the grand ballroom of the 19th century-built Stadthaus located at Halle’s main market square, the series is open to the public and aimed at physicians in the region, researchers and students from the medical and natural science faculties of the Martin-Luther-University, as well as experts from local companies and the interested general public.
The lecture series aims to stimulate scientific discussions and to foster a growing network of collaborations in a wide range of biomedical research areas such as genomics, proteomics, cell signaling, human malignancies and chemical biology.
Historischer Saal im Stadtmuseum Halle
Große Märkerstr. 10
06108 Halle (Saale)
13 MarchOctober 2017, 7 p.m.
Chas Bountra is chief scientist at the Oxford branch of the Structural Genomics Consortium (SGC), Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at Imperial College, London. His current interests are i) using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients ii) focussing on epigenetic and genetically identified proteins, because these are likely to represent better targets for drug discovery, for many cancer, inflammatory, metabolic and neuro-psychiatric diseases iii) working with colleagues in Oxford to build major programmes in rare diseases and in Alzheimers Disease, and creating a “BioEscalator” for the rapid translation of SGC science and iv) building stronger links with local hospitals, patient groups, regulatory agencies, private investors, CROs, biotechs and large pharma companies, to create a new, more efficient ecosystem for pioneer drug discovery.
19 October 2016, 7 p.m.
Adrian L. Harris
Adrian Harris is a Professorial Fellow of St Hugh‘s College in Oxford and a Consultant Medical Oncologist at the Oxford University Hospitals NHS Trust. He was also the Director of Molecular Oncology Laboratory at the University of Oxford, now merged into the Department of Oncology.
Adrian received his bachelor‘s degree in Medicine and Surgery in 1973 at Liverpool University and undertook an intercalated Biochemistry degree there, followed by a DPhil from Oxford University, where he conducted research on mechanisms of resistance to anti-cancer drugs from 1975 to 1978. He then took up a lectureship at the Royal Marsden Hospital in London where he developed an interest in the endocrine therapy of breast cancer with Prof. Ian Smith, and helped to develop early aromatase inhibitors. In 1981 he was appointed Professor of Clinical Oncology at the University of Newcastle Upon Tyne and in 1988 he was invited to Oxford to take up the foundation chair in Medical Oncology and lead the CRUK Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine, one of the leading basic science institutes in the United Kingdom. His long-standing research interests are in cancer biology and therapy, with some focus on breast cancer, angiogenesis and hypoxia and, more recently, cancer metabolism.
19 September 2016, 7 p.m.
Ahmed Ashour Ahmed
Ahmed A. Ahmed is a Professor of Gynaecological Oncology at the Nuffield Department of Obstetrics and Gynaecology at the University of Oxford and a Fellow of St Hugh’s College. Ahmed leads laboratory-based translational research in Gynaecological Oncology. His main interest is in the surgical, medical and fundamental research into ovarian cancer. Ahmed graduated from Ain Shams University in Cairo, Egypt and completed his PhD and Gynaecological Oncology Surgical training at the University of Cambridge. He gained postdoctoral research experience both at the University of Cambridge and at the University of Texas, M.D. Anderson Cancer Centre in the USA. Prof. Ahmed‘s laboratory research focuses on personalization of therapy to circumvent drug resistance in cancer.
30 May 2016, 7 p.m.
Regulation of the protein lifespan is key for most biological processes. When proteins reach the end of their lifetime, most of them get modified by the attachment of ubiquitin (Ub). This has been implicated in the elimination of damaged proteins, but also in physiological proteolytic control of processes such as transcription, signal transduction, and cell cycle transitions. So far, the analyses have focused on Ub attachment, with several hundred Ub conjugating enzymes characterized to date. Much less is known about enzymes that remove Ub from substrate proteins, yet around a hundred genes have been identified, sharing consensus motifs for deubiquitylating enzymes (DUBs). Such diversity is inconsistent with a simple recycling function and strongly suggests a range of specific (but currently largely undiscovered) biological functions. Members of the DUB family are already known to contribute to neoplastic transformation and are implicated in neurodegenerative diseases, making them attractive targets for drug design.
11 April 2016, 7 p.m.
Christian Eggeling studied Physics, initially in Hamburg and then in Göttingen, where he also conducted his diploma and PhD research focused on fluorescence microscopy. After an interim period from 2000 to 2003, working for the company Evotec OAI in Hamburg, he joined the group of Stefan Hell at the Max-Planck-Institute for Biophysical Chemistry in Göttingen as a scientist, contributing to their seminal work until 2012, when he became a group leader and head of the Wolfson Imaging Centre at the Weatherall Institute of Molecular Medicine in Oxford.
29 February 2016, 7 p.m.
Valentine M. Macaulay
Val Macaulay’s clinical interests are in melanoma, and in exploring the potential of novel signaling inhibitors to enhance sensitivity to conventional anti-cancer treatments. The main aim of her research is to understand the contribution of insulin-like growth factor (IGF) signalling to cancer biology. IGF-1 binds to receptors that are expressed on the surface of cancer cells, activating intracellular signalling pathways that promote cell growth, invasion and resistance to killing by cancer treatments. She has shown that IGF receptors are up-regulated in prostate and renal cancers, and detectable in advanced primary tumours and metastatic disease.
14 September 2015, 7 p.m.
Stefan Knapp studied Chemistry in Marburg (Germany) and the University of Illinois (USA). He obtained his PhD in protein crystallography at the Karolinska Institute (Sweden) in 1996 and continued as a postdoctoral scientist. In 1999, he joined Pharmacia as principal research scientist in. He left the company in 2004 to set up a research group at the Structural Genomics Consortium in Oxford (SGC). Since 2008 he is a Professor at the Nuffield Department of Clinical Medicine (NDM) at Oxford University and since Mai 2012 Director for Chemical Biology at the Target Discovery Institute (TDI). His research interests are structural mechanisms that regulate signal transduction pathways, in particular protein kinases and the rational design and the development of selective inhibitors. A current focus of his research team is the development of protein interactions inhibitors (PPIs) that target epigenetic reader domains such as bromodomains.
8 June 2015, 7 p.m.
Tudor A. Fulga
Tudor A. Fulga obtained his PhD from the EMBL in Heidelberg. He subsequently conducted research at Harvard Medical School as postdoctoral fellow and instructor in Cell Biology. In 2011, he joined the Weatherall Institute of Molecular Medicine (WIMM) in Oxford as a Group Leader and MRC senior research fellow. In 2014 he was appointed Associate Professor of Genome Biology. During his PhD, he studied the process of protein translocation across the ER and mechanisms guiding invasive cell migration. At Harvard, Tudor investigated the molecular mechanisms underlying Alzheimer’s disease. Amongst several other important scientific contributions, he delineated the actin cytoskeleton as a critical mediator of neurodegeneration. Subsequently, he pioneered transgenic miRNA competitive inhibitors (miR-sponges), a highly versatile in vivo technology for conditional knockdown of miRNA activity with precise spatial-temporal resolution. His research program in Oxford is focused on deciphering the role of non-coding RNAs in development and diseases, and molecular mechanisms of miRNA target recognition and silencing. He also aims to repurpose the functionality contained within RNAs to develop logic-function molecular devices that are capable of rewiring cellular behavior. The resulting synthetic devices have potential for widespread applications, ranging from basic tools for miRNA research to components in targeted diagnostic and therapeutic strategies.
13 April 2015, 7 p.m.
Anna Schuh is a consultant haematologist at Oxford University Hospitals. Her main research interests are with chronic lymphocytic leukaemia (CLL) and molecular diagnostics. She is a principle/chief investigator on a number of early and late phase clinical trials in CLL. As the head of Translational Molecular Diagnostics she leads on a translational research programme for the development, validation, standardisation and evaluation of clinical utility of NGS technologies. Her particular focus is with improving response prediction in CLL and other malignancies using whole genome sequencing.
12 January 2015, 7 p.m.
Dr Eric O’Neill is a Cancer Research UK Senior Group Leader at the CRUK/MRC Oxford Institute for Radiation Oncology in Oxford and heads the Signalling Group. The overarching aim of his group’s research is to elucidate key stages and molecular players in tumour cell signalling and to use this understanding to enhance treatment strategies and patient response to treatment. Dr O’Neill obtained his BA in microbiology from Trinity College Dublin, Ireland, his MPhil in molecular biology from the University of Umeå, Sweden and his PhD in Cell and Molecular Biology also from the University of Umeå. After a year in Oxford as a Research Associate within the Department of Pharmacology, he was awarded a Marie Curie individual fellowship and completed a five-year post-doctoral position at the Beatson Institute for Cancer Research in Glasgow, before returning to Oxford in 2007 as a Group Leader.
Stephan M. Feller
Section Tumor Biology
Institute of Molecular Medicine
ZAMED (Centre for Applied Medical Research)
06120 Halle (Salle)